Dosage of Mykohaug in details
Usual Adult Dose for Tinea Corporis
Apply Mykohaug topical in a quantity sufficient to cover the affected area and immediately surrounding skin twice a day for 4 weeks, depending on the nature and severity of the infection.
Usual Adult Dose for Tinea Cruris
Apply Mykohaug topical in a quantity sufficient to cover the affected area and immediately surrounding skin twice a day for 2 weeks, depending on the nature and severity of the infection.
Usual Adult Dose for Tinea Pedis
Apply Mykohaug topical in a quantity sufficient to cover the affected area and immediately surrounding skin twice a day for 4 to 8 weeks, depending on the nature and severity of the infection.
Usual Adult Dose for Cutaneous Candidiasis
Apply Mykohaug topical in a quantity sufficient to cover the affected area and immediately surrounding skin twice a day for 2 to 4 weeks, depending on the nature and severity of the infection.
Usual Adult Dose for Tinea Versicolor
Apply Mykohaug topical in a quantity sufficient to cover the affected area and immediately surrounding skin twice a day for 2 to 4 weeks, depending on the nature and severity of the infection.
Usual Adult Dose for Vaginal Candidiasis
Regimen 1: 100 mg (one 100 mg vaginal suppository) intravaginally once a day for 7 consecutive days alone or in combination with topical application of 1% Mykohaug cream to affected area two times daily for 7 consecutive days.
Regimen 2: 200 mg (one 200 mg vaginal suppository) intravaginally once a day for 3 consecutive days alone or in combination with topical application of 1% Mykohaug cream to affected area two times daily for 7 consecutive days.
Regimen 3: 500 mg (one 500 mg vaginal suppository) intravaginally once.
Regimen 4: One applicatorful of 1% Mykohaug vaginal cream intravaginally once daily (preferably at bedtime) for 7 consecutive days.
Regimen 5: One applicatorful of 2% Mykohaug vaginal cream intravaginally once daily (preferably at bedtime) for 3 consecutive days.
Studies have shown the three and seven day courses of Mykohaug to be equally effective. Patient compliance may be increased with a three day course. Patients who fail to achieve a cure with a single 500 mg dose should be treated with a 3 or 7 day course of Mykohaug.
Weekly or monthly Mykohaug vaginal suppositories appear to be effective topical regimens for chronic suppressive therapy in female patients with HIV.
Usual Pediatric Dose for Tinea Corporis
> 3 years: Apply Mykohaug topical in a quantity sufficient to cover the affected area and immediately surrounding skin twice a day for 4 weeks, depending on the nature and severity of the infection.
Usual Pediatric Dose for Tinea Cruris
> 3 years: Apply Mykohaug topical in a quantity sufficient to cover the affected area and immediately surrounding skin twice a day for 2 weeks, depending on the nature and severity of the infection.
Usual Pediatric Dose for Tinea Pedis
> 3 years: Apply Mykohaug topical in a quantity sufficient to cover the affected area and immediately surrounding skin twice a day for 4 to 8 weeks, depending on the nature and severity of the infection.
Usual Pediatric Dose for Cutaneous Candidiasis
> 3 years: Apply Mykohaug topical in a quantity sufficient to cover the affected area and immediately surrounding skin twice a day for 2 to 4 weeks, depending on the nature and severity of the infection.
Usual Pediatric Dose for Tinea Versicolor
> 3 years: Apply Mykohaug topical in a quantity sufficient to cover the affected area and immediately surrounding skin twice a day for 2 to 4 weeks, depending on the nature and severity of the infection.
Usual Pediatric Dose for Vaginal Candidiasis
> 12 years: Regimen 1: 100 mg (one 100 mg vaginal suppository) intravaginally once a day for 7 consecutive days alone or in combination with topical application of 1% Mykohaug cream to affected area two times daily for 7 consecutive days.
Regimen 2: 200 mg (one 200 mg vaginal suppository) intravaginally once a day for 3 consecutive days alone or in combination with topical application of 1% Mykohaug cream to affected area two times daily for 7 consecutive days.
Regimen 3: 500 mg (one 500 mg vaginal suppository) intravaginally once.
Regimen 4: One applicatorful of 1% Mykohaug vaginal cream intravaginally once daily (preferably at bedtime) for 7 consecutive days.
Studies have shown the three and seven day courses of Mykohaug to be equally effective. Patient compliance may be increased with a three day course. Patients who fail to achieve a cure with a single 500 mg dose should be treated with a 3 or 7 day course of Mykohaug.
Weekly or monthly Mykohaug vaginal suppositories appear to be effective topical regimens for chronic suppressive therapy in female patients with HIV.
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Dialysis
Data not available
What other drugs will affect Mykohaug?
Since Mykohaug is not absorbed by your body, drug interactions are not expected. Talk to your doctor and pharmacist before taking any other prescription or over-the-counter medicines.
Mykohaug interactions
Mykohaug should be used cautiously in patients with hyperthyroidism, hypertension and cardiac arrhythmias. All vasopressors should be used cautiously in patients taking monoamine oxidase (MAO) inhibitors.
Mykohaug should not be administered concomitantly with other sympathomimetic drugs (such as isoproterenol) because of possible additive effects and increased toxicity.
Combined effects may induce serious cardiac arrhythmias. They may be administered alternately when the preceding effect of other such drug has subsided.
Administration of epinephrine to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia.. When encountered, such arrhythmias may respond to administration of a beta-adrenergic blocking drug. Mykohaug also should be used cautiously with other drugs (e.g., digitalis, glycosides) that sensitize the myocardium to the actions of sympathomimetic drugs.
Diuretic agents may decrease vascular response to pressor drugs such as epinephrine.
Mykohaug may antagonize the neuron blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter.
References
- DailyMed. "BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- FDA/SPL Indexing Data. "G07GZ97H65: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
- MeSH. "Anti-Infective Agents, Local". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Mykohaug are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Mykohaug. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported frequency of use
No survey data has been collected yet1 consumer reported doses
What doses of Mykohaug drug you have used?The drug can be in various doses. Most anti-diabetic, anti-hypertensive drugs, pain killers, or antibiotics are in different low and high doses and prescribed by the doctors depending on the severity and demand of the condition suffered by the patient. In our reports, ndrugs.com website users used these doses of Mykohaug drug in following percentages. Very few drugs come in a fixed dose or a single dose. Common conditions, like fever, have almost the same doses, e.g., [acetaminophen, 500mg] of drug used by the patient, even though it is available in various doses.
| Users | % | ||
|---|---|---|---|
| 101-200mg | 1 | 100.0% | |
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
